Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

~16 mi. (Lárisa, Greece, +93 more cities)

University General Hospital of Larissa ( Site 0302)

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

~16 mi. (Lárisa, Greece, +130 more cities)

University Hospital of Larissa ( Site 0301)

Bladder Urothelial Carcinoma

BCG solution, +1 more drug

immunotherapy

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

~16 mi. (Lárisa, Greece, +180 more cities)

Exelixis Clinical Site #97

Prostate Adenocarcinoma

atezolizumab, +1 more drug

immunotherapy, +1 more type

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

~16 mi. (Lárisa, Greece, +108 more cities)

University General Hospital of Larissa

BCR-ABL1 Fusion, +1 more biomarker

Acute Lymphoblastic Leukemia

cytarabine, +5 more drugs

chemotherapy, +2 more types

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

~16 mi. (Lárisa, Greece, +87 more cities)

University General Hospital of Larissa

ALK Fusion

Non-Small Cell Lung Carcinoma

brigatinib

targeted therapy

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

~61 mi. (Yeraklíon, Greece, +192 more cities)

University General Hospital of Heraklion

ER Positive, +1 more biomarker

Breast Carcinoma

abemaciclib, +1 more drug

hormone therapy, +1 more type

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

~61 mi. (Yeraklíon, Greece, +356 more cities)

University General Hospital of Heraklion

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

~61 mi. (Yeraklíon, Greece, +172 more cities)

University General Hospital of Heraklion

RET Fusion

Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

~61 mi. (Yeraklíon, Greece, +122 more cities)

University General Hospital of Herakleion ( Site 1202)

Small Cell Lung Carcinoma

etoposide, +5 more drugs

chemotherapy, +3 more types

A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

~61 mi. (Yeraklíon, Greece, +197 more cities)

University General Hospital of Heraklion PA.G.N.I /ID# 214075

BCR-ABL1 Fusion, +47 more biomarkers

Acute Myeloid Leukemia

azacitidine, +1 more drug

chemotherapy

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

~61 mi. (Yeraklíon, Greece, +184 more cities)

University General Hospital of Heraklion

RET Fusion

Non-Squamous Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

~61 mi. (Yeraklíon, Greece, +156 more cities)

University General Hospital of Heraklion PA.G.N.I /ID# 222879

IGH-CCND1 Fusion, +1 more biomarker

Multiple Myeloma

dexamethasone, +1 more drug

chemotherapy, +1 more type